A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1560 participants.

Also called NCT07743450

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,560 participants (planned count) (from the registry)
Sponsor
Ascletis Pharma (China) Co., Limited (from the registry)
Registry
  • NCT NCT07743450
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Czechia, Germany, Greece, Poland, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07743450. Randomized; triple masking; primary purpose treatment. Start 2026-08-28 (actual); primary completion 2028-07 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Acronym
AURORA-2
Condition
Obesity
Condition
Overweight
Condition
Chronic Weight Management
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
ASC30 tablets A1
Intervention (Drug)
Placebo
Lead sponsor
Ascletis Pharma (China) Co., Limited (class: industry)

Record details

Record id
cardio:ct-nct07743450
Content hash
0a656e6b7f637799581c997833262d080f44793eb1f857a14aeadfc65aafbe5f